ABSTRACT
When a patient with chronic kidney disease suffers a fragility fracture, a key question is whether the patient has osteoporosis or, instead, renal osteodystrophy. Bone densitometry does not help in this distinction: biochemical tests, and sometimes also bone biopsy, are needed. However, even if the patient has osteoporosis, we have little evidence to guide our treatment decisions in cases of advanced chronic kidney disease.
Footnotes
↵* The author has disclosed that he has received scientific grants from Amgen, Eli Lilly, Merck & Co, Novartis Pharmaceuticals, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis companies; and honoraria for speaking, advising, or consulting from Amgen, Eli Lilly, GlaxoSmithKline, Merck & Co, Novartis Pharmaceuticals, NPS, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis companies.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.